What Перитол Treats: Main Uses and Benefits

Перитол (Cyproheptadine) is commonly used to provide supportive relief across several key symptom domains. This medication is applied in situations involving certain distressing symptoms, including those associated with allergic rhinitis (hay fever), allergic conjunctivitis, and uncomplicated allergic skin manifestations like hives (urticaria) and pruritus (itching). It is also relevant in contexts where additional symptomatic support is needed for poor appetite and, in a prophylactic role, for recurrent vascular headaches.

---

The medication is relevant for managing symptoms that create noticeable physiological strain, and it contributes to improved comfort during symptomatic periods. It is commonly used to help with groups of symptoms that may appear suddenly or intensify over time, providing support that may help ease the overall symptom burden. The application is common in scenarios requiring short-term symptomatic assistance, particularly for allergic episodes and for patients, including children, who require additional symptomatic assistance for poor appetite.

---

Quick Fact: Relief for Intense Itching and Appetite Loss

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Перитол? (Cyproheptadine)

Official regulatory documentation establishes specific populations and conditions that determine eligibility for Перитол use. The medicine is generally approved for use in adults and children aged two years and older.

Absolute Contraindications

Перитол use is contraindicated and must be avoided in the following groups:

• Infants and Children: Newborn or premature infants.
• Mothers: Nursing mothers (breastfeeding women).
• Elderly: Elderly, debilitated patients.
• Concomitant Therapy: Patients receiving Monoamine Oxidase (MAO) inhibitors.
• Hypersensitivity: Patients with known sensitivity to cyproheptadine or related compounds.

Age-Related Eligibility and Limitations

Age Group	Eligibility Status (Regulatory Labeling)
Children under 2 years	Use Not Established (Safety and effectiveness have not been established.)
Children 2 years and older	Approved (Use is established for labeled purposes.)

Contraindications Based on Medical Conditions

Use is also prohibited in patients with the following conditions, often due to the drug's anticholinergic effects:

• Acute asthmatic attack
• Angle-closure glaucoma
• Conditions causing gastric outlet obstruction (e.g., stenosing peptic ulcer, pyloroduodenal obstruction)
• Conditions causing urinary retention (e.g., symptomatic prostatic hypertrophy, bladder neck obstruction)

Populations Requiring Conditional Use

Caution is advised in patients with a history of bronchial asthma, hyperthyroidism, hypertension, cardiovascular disease, increased intraocular pressure, and underlying hepatic or renal impairment.

The official prescribing information for Перитол (Cyproheptadine) documents interactions primarily based on pharmacodynamic effects, where the co-administration of certain substances results in additive or antagonistic outcomes.

Interaction Classification	Interacting Substances / Categories
Contraindicated Combinations	Monoamine Oxidase Inhibitors (MAOIs).
Pharmacodynamic Reinforcement	Central Nervous System (CNS) Depressants (e.g., sedatives, hypnotics, anti-anxiety agents); Alcohol.
Pharmacodynamic Antagonism	Serotonin-enhancing Antidepressants (SSRIs).

Official Interaction Statements:

• Co-administration with MAO Inhibitors is strictly contraindicated because MAOIs are documented to prolong and intensify the anticholinergic effects of Cyproheptadine.
• Antihistamines have additive depressant effects with alcohol and other CNS Depressants (including sedatives and tranquilizers), a fact noted in the official regulatory label.
• The medication’s anti-serotonin activity may interfere with Serotonin-enhancing Antidepressants, potentially resulting in the recurrence of depressive symptoms.
• Tricyclic Antidepressant Drugs (TCAs) may yield a false positive test result during drug screening procedures.
• Elderly and debilitated patients are listed as a contraindication in the prescribing information due to their high susceptibility to effects (e.g., sedation, dizziness) that are compounded by pharmacodynamic interactions.

Connection to the overall interaction profile

Regulatory documents define the product’s interaction structure through mandatory "do not combine" rules for MAOIs and formal statements of clinically significant pharmacodynamic outcomes. The profile explicitly highlights the risks associated with additive CNS depression and the antagonism of serotonergic effects.

Перитол (Cyproheptadine) functions as a competitive antagonist primarily at multiple neurotransmitter receptor sites. Its mechanism of action centers on high-affinity binding to Histamine H1 receptors (H1R) and Serotonin 5-HT2 receptors (5- HT2R), including the 5- HT2A and 5- HT2C subtypes, located in both central and peripheral tissues.

At the cellular level, its binding to the H1R site competitively inhibits the binding and subsequent signaling cascade initiated by endogenous histamine, thereby modulating histamine-mediated cellular responses in the gastrointestinal tract, blood vessels, and respiratory tract. Concurrently, antagonism of the 5- HT2A receptor in the central nervous system, particularly within the hypothalamus, modifies serotonergic activity, which is linked to downstream effects on energy homeostasis and feeding behavior. Furthermore, the compound exhibits anticholinergic activity through antagonism of muscarinic acetylcholine receptors, which further contributes to system-level physiological modulation by influencing smooth muscle tone and glandular secretion across various organ systems.

How to Use Перитол (Cyproheptadine): Administration Guidelines

Administration of Перитол (Cyproheptadine) is limited to the oral route, utilizing the standard dosage forms: the 4 mg tablet and the 2 mg/5 mL syrup. The availability of the syrup facilitates dose precision and administration for patients who require liquid medication or doses smaller than a full tablet.

---

Standard Dosing and Frequency

The dosage is individualized based on the patient's response and size, and is typically aligned with established limits:

Population	Initial Dose	Maintenance Dose Range	Maximum Daily Dose
Adults	4 mg three times a day (TID)	4 mg to 20 mg per day	32 mg per day

Because the effect of a single dose lasts approximately four to six hours, the total daily requirement is administered in divided doses (typically two or three times daily) to provide continuous symptomatic relief. The medication can be taken without regard to meals (with or without food).

---

Dosing for Specific Populations

Standard practice includes specific dose modifications for certain patient groups:

• Pediatric Patients: Dosing is weight-based or age-specific, with a maximum of 12 mg per day for ages 2–6 and 16 mg per day for ages 7–14.
• Older Adults: Treatment should begin at the low end of the usual adult dose range, reflecting the need for caution.
• Renal/Hepatic Impairment: Lower doses and close monitoring are necessitated by diminished drug elimination in these conditions.

Research evidence / Overview of studies for Перитол

The clinical record and research for Перитол (Cyproheptadine) are based on evidence for the study of allergic conditions and a significant body of research was studied for appetite. Research findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain.

---

Evidence for Use in Allergic Conditions

Research for the use of Перитол was studied for allergic conditions and is primarily relevant in trials assessing short-term or acute symptom episodes. The research base includes historical regulatory reports and older studies that were used to establish its historical classification as an antihistamine. Studies was evaluated in research contexts involving fluctuating or unstable symptoms in adults and children with conditions characterized by fluctuating or episodic manifestations.

Research examined outcomes related to physical discomfort, focusing on measures of symptom change for allergic rhinitis and skin manifestations, including hives (urticaria) and itching (pruritus). A limitation in this area is that the research landscape includes limited modern, large-scale, controlled data, and comparative evidence is lacking against newer, more selective antihistamine compounds.

---

Evidence for Appetite Stimulation and Weight Gain

Research was studied for its role in appetite and weight gain and is supported by a mix of Systematic Reviews and multiple Randomized Controlled Trials (RCTs). Studies explored the effects in populations including pediatric patients (children and adolescents) and adults with weight loss associated with various chronic conditions.

Research examined objective changes in Body Weight and shifts in Body Mass Index (BMI) over defined time intervals. Systematic reviews data show patterns related to measured changes in body weight across various study populations during the study period. What remains uncertain is the heterogeneity of the health conditions in the populations studied, which may make it challenging to apply findings broadly.

---

Studies on Recurrent Vascular Headaches

Research was studied for recurrent vascular headaches (migraine prophylaxis), particularly in younger individuals. This evidence is generally derived from smaller-scale Randomized Controlled Trials (RCTs), open-label studies, and retrospective case reviews. The research examined outcomes related to episodic or acute changes in headache frequency and severity in children and adolescents.

The overall certainty remains low due to a lack of high-quality, large-scale controlled data for this use. The body of evidence for migraine prophylaxis is cited in scientific literature as providing limited empirical data, and evidence quality varies across studies.

Key Studies & References

1. MedlinePlus: Cyproheptadine (Medication Overview)

Common questions about Перитол (FAQ)

Q: Can I drink alcohol while taking this medicine?

Regulatory documents advise that alcoholic beverages should be avoided while undergoing treatment. Taking this medicine with alcohol may increase central nervous system (CNS) side effects, such as feelings of dizziness or increased sleepiness (somnolence).

Q: Can I take this medication if I am pregnant or breastfeeding?

Official product information states that this medicine may cause potential harm to the developing fetus. Individuals who are pregnant or may become pregnant are advised of this potential risk. Furthermore, breastfeeding is not recommended during treatment because the medication can pass into breast milk.

Q: Does this medicine cause weight gain?

According to the safety information reported in clinical trials, weight gain is listed as a commonly experienced side effect for individuals taking this medication.

Q: Can this drug be stopped suddenly?

Official safety information recommends that this medicine be withdrawn gradually (e.g., over a minimum of one week). Rapid discontinuation can increase the risk of seizures or other adverse reactions.

Q: Can I drive or operate machinery after taking this?

Official labeling states that the medicine commonly causes dizziness and somnolence (sleepiness), which can impair your judgment and reaction time. You should not drive or operate complex machinery until you have determined how the medicine affects your level of alertness and coordination.

Q: What is the recommended storage temperature?

The recommended storage instructions state that the medication should be stored in its original packaging at room temperature. This is typically defined as a range between 15°C to 30°C (59°F to 86°F).

Q: Can children use this medicine?

In the United States, the medicine is officially indicated for treating partial-onset seizures in patients 1 month of age and older. However, for other approved uses, such as neuropathic pain, the safety and effectiveness have not been established in children and adolescents under 17 years of age.

Q: Does it cause sleepiness?

Yes, sleepiness (somnolence) and dizziness are listed in regulatory documents as the most common adverse reactions reported during clinical trials for this medicine.

Q: What if I have an allergic reaction?

Official safety information includes reports of serious allergic reactions, including hypersensitivity and angioedema (swelling of the face, mouth, tongue, or neck). If you experience signs of a serious allergic reaction, you should seek emergency medical assistance immediately and stop using the medicine as advised by a healthcare professional.

Q: Will this medicine interact with my blood pressure medicine?

Regulatory information indicates that caution is necessary when taking this medicine alongside certain medications for diabetes, specifically thiazolidinediones, as this combination may increase swelling (peripheral edema). It is important to review all current medications with a healthcare provider.

How to Store and Dispose of Peritol (Cyproheptadine)

Storage and disposal instructions for Peritol are governed by official regulatory standards to maintain product quality and ensure safety.

---

Mandatory Storage Conditions

The required storage temperature for both the tablets and the oral solution (syrup) is 20 to 25 C (68 to 77 F), defined as USP Controlled Room Temperature. The oral solution must be protected from freezing.

Dosage Form	Container Requirements	Protection Constraints
Tablets	Must be dispensed in a well-closed container with a child-resistant closure.	Store away from excess moisture.
Oral Solution	Must be dispensed in a tight, light-resistant container.	Protect from light; Do not freeze.

---

Handling and Disposal

All forms of this medicine must be kept out of the sight and reach of children. Official patient labeling typically does not provide explicit household disposal instructions for unused medicine. Disposal should be carried out according to general local pharmaceutical waste guidelines.